Mehl B, Santell J P
Department of Pharmacy, Mount Sinai Medical Center, New York, NY, USA.
Am J Health Syst Pharm. 1998 Jan 15;55(2):127-36. doi: 10.1093/ajhp/55.2.127.
Drug cost projections for 1998, factors that directly influence drug costs, and tools for projecting drug expenditures are discussed. The producer price index indicates that prices for drugs and pharmaceuticals increased 2.1% between January and June 1997; the increase for prescription preparations was 2.7%. Medi-Span data show an average increase for all drug products of 1.02% during the first six months of 1997; First Data-Bank reports a 1.7% increase for the same period. IMS America data, which take account of weighting for individual drugs or drug classes, show the prices of all drugs increasing 2.3% between the second quarters of 1996 and 1997. Drug industry analysts project the overall price increase in the next 12 months at 2-4%. Group purchasing organizations predict an average increase over the next 12 months of 0.56% for contracted drugs and 3.6% for noncontracted drugs. Various health care provider indexes suggest that increases in drug costs could be smaller over the next few years. The current trend of takeovers and mergers of pharmaceutical companies and health systems is likely to continue into 1998. As a result of generic competition and the loss of patent protection for many pharmaceutical products, the number of drugs to be introduced onto the market and the number of drugs in development are expected to escalate until the year 2000. These and other major changes in the health care environment, including changes in drug distribution and controversies over the use of formularies, will make future forecasting difficult. Compared with previous years, smaller increases in drug costs have been projected for 1998 and beyond, but changes in the health care environment mean that greater knowledge will be required to forecast future drug expenditures.
讨论了1998年的药品成本预测、直接影响药品成本的因素以及预测药品支出的工具。生产者价格指数表明,1997年1月至6月期间药品和制药价格上涨了2.1%;处方药制剂的涨幅为2.7%。Medi-Span数据显示,1997年前六个月所有药品的平均涨幅为1.02%;First Data-Bank报告同期涨幅为1.7%。IMS America的数据考虑了个别药品或药品类别的权重,显示1996年第二季度至1997年期间所有药品的价格上涨了2.3%。制药行业分析师预计未来12个月的总体价格涨幅为2%至4%。集团采购组织预测,未来12个月合同药品的平均涨幅为0.56%,非合同药品的平均涨幅为3.6%。各种医疗保健提供者指数表明,未来几年药品成本的涨幅可能会更小。制药公司和医疗系统目前的收购和合并趋势可能会持续到1998年。由于仿制药竞争以及许多药品专利保护的丧失,预计到2000年投放市场的药品数量和正在研发的药品数量将会增加。医疗保健环境中的这些以及其他重大变化,包括药品分销的变化和药品处方集使用方面的争议,将使未来的预测变得困难。与前几年相比,预计1998年及以后药品成本的涨幅会更小,但医疗保健环境的变化意味着需要更多知识来预测未来的药品支出。